Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2/3 1Phase 2 1

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Conditions

Breast Neoplasms 2400Neoplasms 1819Carcinoma, Non-Small-Cell Lung 1599Prostatic Neoplasms 1298Colorectal Neoplasms 1140Lung Neoplasms 984Neoplasm Metastasis 830Multiple Myeloma 792Leukemia, Myeloid, Acute 767Ovarian Neoplasms 674Pancreatic Neoplasms 662Melanoma 660Squamous Cell Carcinoma of Head and Neck 586Carcinoma, Hepatocellular 567Recurrence 562Brain Neoplasms 527Glioblastoma 513Head and Neck Neoplasms 500Stomach Neoplasms 497Triple Negative Breast Neoplasms 465Lymphoma 454Uterine Cervical Neoplasms 450Carcinoma, Renal Cell 425Precursor Cell Lymphoblastic Leukemia-Lymphoma 410Lymphoma, Non-Hodgkin 389Endometrial Neoplasms 381Sarcoma 368Lymphoma, Follicular 356Urinary Bladder Neoplasms 354Hematologic Neoplasms 352

Interventions

Alpelisib 2mirdametinib 1Injections, Intralesional 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Lymphatic Abnormalities × 1 year × Clear all
NCT05948943 2026-06-02

EPIK-L1

Novartis

Phase 2/3 Recruiting
232 enrolled

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

NCT05983159 2026-05-05

TARGET-VM

Murdoch Childrens Research Institute

Phase 2 Recruiting
50 enrolled

Arteriovenous Malformations, Lymphangioma, Skin Diseases, Vascular, Lymphangioma, Cystic, Lymphatic Abnormalities, Vascular Malformations

NCT07189832 2026-04-28

Bleomycin Intralesional Injections of Cystic Hygromas

Delta University for Science and Technology

Phase NA Completed
30 enrolled

Lymphangioma, Cystic, Lymphatic Abnormalities

NCT06239480 2026-03-27

SELVA

Palvella Therapeutics, Inc.

Phase 3 Active not recruiting
51 enrolled

Congenital Abnormalities, Lymphangioma, Lymphatic Abnormalities, Vascular Malformations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡